A Study of Imvotamab in Severe Systemic Lupus Erythematosus
Status:
TERMINATED
Trial end date:
2025-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies.
Participants will be given imvotamab through a vein (i.e., intravenously).